As a Partner in L2 Consulting, Leigh Berryman is a serial Chief Executive Officer who has provided leadership to companies in Europe, North America and Asia. Trained as a toxicologist, he has been involved and directed drug development programs for over 35 years and has led or contributed to over 300 IND applications and first-in-man programs across Europe and North America. In particular, he was a lead scientist for one of the pioneering recombinant products, rhEPO.
From this scientific foundation, Leigh progressed into executive management in the mid-90’s, founding and ultimately taking public (Toronto Stock eXchange), his own company LAB Research Inc. (“LAB”). Thereafter he provided turnaround leadership to Ricerca LLC (in Ohio), a 300+ person company, doubling revenues and enabling capital investment for growth and M&A activity over a 2 year period. He stepped into another CEO role in Singapore (Maccine Pte. Ltd.) and, over a 6-year period, brought the company to profitability. Since 2014, he has worked with early stage companies in advisory and consulting roles to design development programs with a focus on cost and timing to enable evaluation of risk and return on required investment capital.
E.L. Berryman B.Sc.(Hons.), MRB. CBiol. RQAP-GLP, Reg. Toxicologist